[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frTWvmWlj63iDtfqUVztFqbohlhOwXGd_e2Tk1aYWakA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University Hospital, Angers",[4],464,false,108,32,504631,20,398,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Peripheral Artery Disease",11,{"name":18,"count":19},"Pseudoxanthoma Elasticum",9,{"name":21,"count":22},"Pulmonary Embolism",8,{"name":24,"count":25},"Septic Shock",7,{"name":27,"count":25},"Peripheral Arterial Disease",{"name":29,"count":30},"Thoracic Outlet Syndrome",6,{"name":32,"count":30},"Healthy",{"name":34,"count":35},"Alzheimer Disease",5,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02416388","Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","2025-07","Idarubicin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05885646","Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes","2025-12-01","Sulthiame",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04288635","Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study","2026-07-09","Whole blood samples",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06007391","Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1","2026-09","Nicotinamide",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06195540","RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","2026-11-19","Rivaroxaban 10 MG",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05710211","Clonal Architecture of ASXL1-mutated Myelofibrosis","2027-04-23","Clonal architecture determination",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04942080","Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","2027-04-28","CALR allele burden quantification",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06999785","Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage","2027-09-01","Blood test",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06320509","Interest of Urinary Oxygen Partial Pressure (PO2u) in Predicting the Onset or Recovery of Acute Renal Failure During Shock States - OXYpi Study","2027-10-18","Continuous measurement of uPO2",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT07258667","Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy","2028-04","Nicotinamide treatment",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,142,160,178,196,214,232,250,268,286,304,330,348,370,395,417,442,464,485,509,531,573,599,626,651,675,693,711,729,756,774,800,818,854,894,919,944,969,996,1014,1032,1057,1082,1100,1118,1148,1166,1189,1214,1232,1258,1281,1306,1333,1351,1378,1396,1414,1432,1458,1486,1504,1528,1546,1574,1598,1622,1647,1671,1718,1762,1797,1825,1850,1879,1897,1915,1933,1951,1969,1987,2005,2023,2041,2065,2091,2118,2143,2169,2196,2214,2232,2256,2281,2299,2324,2342,2367],{"intervention":96,"totalTrials":97,"cells":98},"Cyclosporine",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":118,"PHASE4":138,"NA":140},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT02176733","Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy","UNKNOWN",[90],"2015-10","2011-07",12,[115],"Leber Hereditary Optic Neuropathy",[117],"cyclosporine",{"trials":119,"activeCount":137,"soonestReadout":40},[120],{"nctId":38,"briefTitle":39,"status":121,"phases":122,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"RECRUITING",[90,91],"2032-01","2015-01",3100,[127],"Acute Myeloid Leukemia (AML)",[41,129,130,96,131,132,133,134,135,136],"Daunorubicin","HD Cytarabine","Methotrexate","Mycophenolic acid","vosaroxin","ID cytarabine","Dexamethasone","Venetoclax",1,{"trials":139,"activeCount":101},[],{"trials":141,"activeCount":101},[],{"intervention":41,"totalTrials":137,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":156,"NA":158},{"trials":145,"activeCount":101},[],{"trials":147,"activeCount":101},[],{"trials":149,"activeCount":101},[],{"trials":151,"activeCount":137,"soonestReadout":40},[152],{"nctId":38,"briefTitle":39,"status":121,"phases":153,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":154,"interventions":155},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":157,"activeCount":101},[],{"trials":159,"activeCount":101},[],{"intervention":129,"totalTrials":137,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":174,"NA":176},{"trials":163,"activeCount":101},[],{"trials":165,"activeCount":101},[],{"trials":167,"activeCount":101},[],{"trials":169,"activeCount":137,"soonestReadout":40},[170],{"nctId":38,"briefTitle":39,"status":121,"phases":171,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":172,"interventions":173},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"intervention":130,"totalTrials":137,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":192,"NA":194},{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":101},[],{"trials":185,"activeCount":101},[],{"trials":187,"activeCount":137,"soonestReadout":40},[188],{"nctId":38,"briefTitle":39,"status":121,"phases":189,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":190,"interventions":191},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":193,"activeCount":101},[],{"trials":195,"activeCount":101},[],{"intervention":131,"totalTrials":137,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":210,"NA":212},{"trials":199,"activeCount":101},[],{"trials":201,"activeCount":101},[],{"trials":203,"activeCount":101},[],{"trials":205,"activeCount":137,"soonestReadout":40},[206],{"nctId":38,"briefTitle":39,"status":121,"phases":207,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":208,"interventions":209},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":211,"activeCount":101},[],{"trials":213,"activeCount":101},[],{"intervention":132,"totalTrials":137,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":228,"NA":230},{"trials":217,"activeCount":101},[],{"trials":219,"activeCount":101},[],{"trials":221,"activeCount":101},[],{"trials":223,"activeCount":137,"soonestReadout":40},[224],{"nctId":38,"briefTitle":39,"status":121,"phases":225,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":226,"interventions":227},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":229,"activeCount":101},[],{"trials":231,"activeCount":101},[],{"intervention":133,"totalTrials":137,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":246,"NA":248},{"trials":235,"activeCount":101},[],{"trials":237,"activeCount":101},[],{"trials":239,"activeCount":101},[],{"trials":241,"activeCount":137,"soonestReadout":40},[242],{"nctId":38,"briefTitle":39,"status":121,"phases":243,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":244,"interventions":245},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":247,"activeCount":101},[],{"trials":249,"activeCount":101},[],{"intervention":134,"totalTrials":137,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":264,"NA":266},{"trials":253,"activeCount":101},[],{"trials":255,"activeCount":101},[],{"trials":257,"activeCount":101},[],{"trials":259,"activeCount":137,"soonestReadout":40},[260],{"nctId":38,"briefTitle":39,"status":121,"phases":261,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":262,"interventions":263},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":265,"activeCount":101},[],{"trials":267,"activeCount":101},[],{"intervention":135,"totalTrials":137,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":282,"NA":284},{"trials":271,"activeCount":101},[],{"trials":273,"activeCount":101},[],{"trials":275,"activeCount":101},[],{"trials":277,"activeCount":137,"soonestReadout":40},[278],{"nctId":38,"briefTitle":39,"status":121,"phases":279,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":280,"interventions":281},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":283,"activeCount":101},[],{"trials":285,"activeCount":101},[],{"intervention":136,"totalTrials":137,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":300,"NA":302},{"trials":289,"activeCount":101},[],{"trials":291,"activeCount":101},[],{"trials":293,"activeCount":101},[],{"trials":295,"activeCount":137,"soonestReadout":40},[296],{"nctId":38,"briefTitle":39,"status":121,"phases":297,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":298,"interventions":299},[90,91],[127],[41,129,130,96,131,132,133,134,135,136],{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":101},[],{"intervention":61,"totalTrials":137,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":326,"NA":328},{"trials":307,"activeCount":101},[],{"trials":309,"activeCount":101},[],{"trials":311,"activeCount":101},[],{"trials":313,"activeCount":137,"soonestReadout":60},[314],{"nctId":58,"briefTitle":59,"status":121,"phases":315,"primaryCompletion":60,"completion":60,"start":316,"enrollment":317,"conditions":318,"interventions":324},[91],"2024-07-19",1424,[319,320,21,321,322,323],"Venous Thromboembolism","Deep Vein Thrombosis","Lower Limb Trauma","Thromboprophylaxis","Immobilisation",[61,325],"Low Heparin Molecular Weight",{"trials":327,"activeCount":101},[],{"trials":329,"activeCount":101},[],{"intervention":325,"totalTrials":137,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":344,"NA":346},{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":101},[],{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":137,"soonestReadout":60},[340],{"nctId":58,"briefTitle":59,"status":121,"phases":341,"primaryCompletion":60,"completion":60,"start":316,"enrollment":317,"conditions":342,"interventions":343},[91],[319,320,21,321,322,323],[61,325],{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"intervention":56,"totalTrials":137,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":366,"NA":368},{"trials":351,"activeCount":101},[],{"trials":353,"activeCount":101},[],{"trials":355,"activeCount":101},[],{"trials":357,"activeCount":137,"soonestReadout":55},[358],{"nctId":53,"briefTitle":54,"status":359,"phases":360,"primaryCompletion":55,"completion":55,"start":361,"enrollment":362,"conditions":363,"interventions":365},"ACTIVE_NOT_RECRUITING",[90,91],"2024-01-23",25,[364],"Nicotinamide Adverse Reaction",[56],{"trials":367,"activeCount":101},[],{"trials":369,"activeCount":101},[],{"intervention":86,"totalTrials":137,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":137,"soonestReadout":85},[376],{"nctId":83,"briefTitle":84,"status":377,"phases":378,"primaryCompletion":85,"completion":85,"start":379,"enrollment":380,"conditions":381,"interventions":386},"NOT_YET_RECRUITING",[89],"2026-04",13,[382,383,384,385],"Leber Hereditary Optic Neuropathy (LHON)","Leber's Hereditary Optic Neuropathy (LHON)","Mitochondrial Disease","Optic Nerve Disease",[86],{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[],{"trials":394,"activeCount":101},[],{"intervention":46,"totalTrials":137,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":101},[],{"trials":406,"activeCount":101},[],{"trials":408,"activeCount":137,"soonestReadout":45},[409],{"nctId":43,"briefTitle":44,"status":121,"phases":410,"primaryCompletion":45,"completion":45,"start":411,"enrollment":412,"conditions":413,"interventions":416},[],"2023-10-17",15,[414,415],"Importance of Interictal Epileptiform Activity on Sleep EEG","Epilepsy in Children",[46],{"intervention":71,"totalTrials":137,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":420,"activeCount":101},[],{"trials":422,"activeCount":101},[],{"trials":424,"activeCount":101},[],{"trials":426,"activeCount":101},[],{"trials":428,"activeCount":101},[],{"trials":430,"activeCount":137,"soonestReadout":70},[431],{"nctId":68,"briefTitle":69,"status":121,"phases":432,"primaryCompletion":70,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":441},[93],"2030-04-28","2021-10-28",260,[437,438,439,440],"Myeloproliferative Neoplasm","Essential Thrombocythemia","Primary Myelofibrosis, Prefibrotic Stage","Primary Myelofibrosis, Fibrotic Stage",[71],{"intervention":51,"totalTrials":137,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":445,"activeCount":101},[],{"trials":447,"activeCount":101},[],{"trials":449,"activeCount":101},[],{"trials":451,"activeCount":101},[],{"trials":453,"activeCount":101},[],{"trials":455,"activeCount":137,"soonestReadout":50},[456],{"nctId":48,"briefTitle":49,"status":121,"phases":457,"primaryCompletion":50,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},[],"2026-08-09","2020-07-09",55,[24,462],"Multiple Organ Failure",[51],{"intervention":81,"totalTrials":137,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":467,"activeCount":101},[],{"trials":469,"activeCount":101},[],{"trials":471,"activeCount":101},[],{"trials":473,"activeCount":101},[],{"trials":475,"activeCount":101},[],{"trials":477,"activeCount":137,"soonestReadout":80},[478],{"nctId":78,"briefTitle":79,"status":121,"phases":479,"primaryCompletion":80,"completion":480,"start":481,"enrollment":460,"conditions":482,"interventions":484},[93],"2028-01-18","2024-04-18",[483],"Shock Circulatory",[81],{"intervention":76,"totalTrials":137,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":101},[],{"trials":490,"activeCount":101},[],{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":101},[],{"trials":496,"activeCount":101},[],{"trials":498,"activeCount":137,"soonestReadout":75},[499],{"nctId":73,"briefTitle":74,"status":121,"phases":500,"primaryCompletion":75,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":508},[93],"2027-11-15","2025-07-08",60,[505,506,507],"Hyperbaric Oxygen","Genotoxicity","Malignancy",[76],{"intervention":66,"totalTrials":137,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":512,"activeCount":101},[],{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":101},[],{"trials":520,"activeCount":101},[],{"trials":522,"activeCount":137,"soonestReadout":65},[523],{"nctId":63,"briefTitle":64,"status":121,"phases":524,"primaryCompletion":65,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},[93],"2031-04-23","2023-04-24",50,[529],"Myelofibrosis",[66],{"intervention":532,"totalTrials":97,"cells":533},"Warfarin",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":571},{"trials":535,"activeCount":101},[],{"trials":537,"activeCount":101},[],{"trials":539,"activeCount":101},[],{"trials":541,"activeCount":101},[],{"trials":543,"activeCount":101},[544,555],{"nctId":545,"briefTitle":546,"status":109,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT04073316","AntiCoagulants and COGnition",[92],"2023-02","2020-02-13",48,[552],"Nonvalvular Atrial Fibrillation",[554,532],"Rivaroxaban 20 MG",{"nctId":556,"briefTitle":557,"status":558,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":568},"NCT02161965","Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation","COMPLETED",[92],"2016-12-31","2018-02-16","2013-05-21",51,[565,566,21,567],"Permanent Atrial Fibrillation","Venous Thrombosis","Anticoagulation Treatment at Least > or = to 12-month",[569,570,532],"Rivaroxaban","Fluindione",{"trials":572,"activeCount":101},[],{"intervention":574,"totalTrials":137,"cells":575},"Activated Charcoal",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":597},{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"trials":583,"activeCount":101},[],{"trials":585,"activeCount":101},[586],{"nctId":587,"briefTitle":588,"status":589,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":101,"conditions":594,"interventions":596},"NCT02969746","Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants","WITHDRAWN",[92],"2018-09","2024-09","2014-07-18",[595],"Anticoagulants; Circulating, Hemorrhagic Disorder",[574],{"trials":598,"activeCount":101},[],{"intervention":600,"totalTrials":137,"cells":601},"Collection of blood samples",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":624},{"trials":603,"activeCount":101},[],{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":101},[],{"trials":609,"activeCount":101},[],{"trials":611,"activeCount":101},[612],{"nctId":613,"briefTitle":614,"status":615,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":623},"NCT02618109","Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia","TERMINATED",[92],"2022-09","2016-01",119,[621,622],"B Acute Lymphoblastic Leukemia","Leukemia Relapse",[600],{"trials":625,"activeCount":101},[],{"intervention":627,"totalTrials":137,"cells":628},"Propranolol - Spironolactone",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":637,"NA":649},{"trials":630,"activeCount":101},[],{"trials":632,"activeCount":101},[],{"trials":634,"activeCount":101},[],{"trials":636,"activeCount":101},[],{"trials":638,"activeCount":101},[639],{"nctId":640,"briefTitle":641,"status":615,"phases":642,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT00188045","Hemodynamic Effects of Chronic Administration of Spironolactone and\u002For Propranolol in Alcoholic Cirrhotic Patients",[92],"2003-12","1995-04",54,[647],"Alcoholic Cirrhosis",[627],{"trials":650,"activeCount":101},[],{"intervention":652,"totalTrials":137,"cells":653},"Cholecalciferol",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":673},{"trials":655,"activeCount":101},[],{"trials":657,"activeCount":101},[],{"trials":659,"activeCount":101},[],{"trials":661,"activeCount":101},[],{"trials":663,"activeCount":101},[664],{"nctId":665,"briefTitle":666,"status":558,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":672},"NCT03615833","Pilot Study of Vitamin D Screening Use in Peripheral Arterial Disease Patient Over Maximum Distance Walking",[92],"2020-09-21","2019-03-11",27,[27],[652],{"trials":674,"activeCount":101},[],{"intervention":554,"totalTrials":137,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":691},{"trials":678,"activeCount":101},[],{"trials":680,"activeCount":101},[],{"trials":682,"activeCount":101},[],{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":101},[687],{"nctId":545,"briefTitle":546,"status":109,"phases":688,"primaryCompletion":548,"completion":548,"start":549,"enrollment":550,"conditions":689,"interventions":690},[92],[552],[554,532],{"trials":692,"activeCount":101},[],{"intervention":569,"totalTrials":137,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":709},{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":101},[],{"trials":704,"activeCount":101},[705],{"nctId":556,"briefTitle":557,"status":558,"phases":706,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":707,"interventions":708},[92],[565,566,21,567],[569,570,532],{"trials":710,"activeCount":101},[],{"intervention":570,"totalTrials":137,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":721,"NA":727},{"trials":714,"activeCount":101},[],{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":101},[],{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":101},[723],{"nctId":556,"briefTitle":557,"status":558,"phases":724,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":725,"interventions":726},[92],[565,566,21,567],[569,570,532],{"trials":728,"activeCount":101},[],{"intervention":730,"totalTrials":137,"cells":731},"Lidocaïne",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":754},{"trials":733,"activeCount":101},[],{"trials":735,"activeCount":101},[],{"trials":737,"activeCount":101},[],{"trials":739,"activeCount":101},[],{"trials":741,"activeCount":101},[742],{"nctId":743,"briefTitle":744,"status":558,"phases":745,"primaryCompletion":746,"start":747,"enrollment":748,"conditions":749,"interventions":752},"NCT00727935","Comparison Of The Analgesia Obtained By Infiltration For The Joinings Of Episiotomies (Liropep)",[92],"2007-07","2006-10",165,[750,751],"Parturients","Childbirth",[730,753],"Ropivacaïne",{"trials":755,"activeCount":101},[],{"intervention":753,"totalTrials":137,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":772},{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":101},[],{"trials":765,"activeCount":101},[],{"trials":767,"activeCount":101},[768],{"nctId":743,"briefTitle":744,"status":558,"phases":769,"primaryCompletion":746,"start":747,"enrollment":748,"conditions":770,"interventions":771},[92],[750,751],[730,753],{"trials":773,"activeCount":101},[],{"intervention":775,"totalTrials":137,"cells":776},"Zopiclone",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":798},{"trials":778,"activeCount":101},[],{"trials":780,"activeCount":101},[],{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[787],{"nctId":788,"briefTitle":789,"status":558,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":796},"NCT01549691","Reassessment of Premedication in Surgery",[92],"2013-04","2012-03",455,[795],"Anxiety",[775,797],"Alprazolam",{"trials":799,"activeCount":101},[],{"intervention":797,"totalTrials":137,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":816},{"trials":803,"activeCount":101},[],{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":101},[],{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[812],{"nctId":788,"briefTitle":789,"status":558,"phases":813,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":814,"interventions":815},[92],[795],[775,797],{"trials":817,"activeCount":101},[],{"intervention":819,"totalTrials":97,"cells":820},"Hydroxychloroquine",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":850,"NA":852},{"trials":822,"activeCount":101},[],{"trials":824,"activeCount":101},[],{"trials":826,"activeCount":101},[],{"trials":828,"activeCount":101},[829,839],{"nctId":830,"briefTitle":831,"status":615,"phases":832,"primaryCompletion":833,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":838},"NCT04325893","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease",[91],"2020-06-18","2020-04-01",259,[837],"Coronavirus",[819],{"nctId":840,"briefTitle":841,"status":109,"phases":842,"primaryCompletion":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT03540810","Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome",[91],"2022-08-15","2022-10-15","2018-08-15",300,[848],"Primary Antiphospholipid Syndrome",[819],{"trials":851,"activeCount":101},[],{"trials":853,"activeCount":101},[],{"intervention":855,"totalTrials":97,"cells":856},"Tranexamic Acid",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":890,"NA":892},{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":101},[865,876],{"nctId":866,"briefTitle":867,"status":558,"phases":868,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":875},"NCT02302456","Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery",[91],"2017-01","2017-04","2015-02",4079,[874],"Immediate Postpartum Hemorrhage",[855],{"nctId":877,"briefTitle":878,"status":615,"phases":879,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":886},"NCT02972294","HiFIT Study : Hip Fracture: Iron and Tranexamic Acid",[91],"2021-09-16","2017-03-31",419,[884,885],"Hip Fractures Pathologic","Anemia",[887,855,888,889],"Iron Isomaltoside 1000","Placebos iron isomaltoside 1000","Placebos tranexamic acid",{"trials":891,"activeCount":101},[],{"trials":893,"activeCount":101},[],{"intervention":895,"totalTrials":137,"cells":896},"99mTc-Exametazime (HMPAO)-labeled leukocytes",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":915,"NA":917},{"trials":898,"activeCount":101},[],{"trials":900,"activeCount":101},[],{"trials":902,"activeCount":101},[],{"trials":904,"activeCount":101},[905],{"nctId":906,"briefTitle":907,"status":109,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":911,"conditions":912,"interventions":914},"NCT02538133","Study Assessing Hybrid SPECT-CT With Labeled Leukocytes for Diagnosis of Vascular Prosthesis Infections",[91],"2020-01","2015-09",80,[913],"Vascular Prosthesis Infection",[895],{"trials":916,"activeCount":101},[],{"trials":918,"activeCount":101},[],{"intervention":920,"totalTrials":137,"cells":921},"Mouthwashes",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":940,"NA":942},{"trials":923,"activeCount":101},[],{"trials":925,"activeCount":101},[],{"trials":927,"activeCount":101},[],{"trials":929,"activeCount":101},[930],{"nctId":931,"briefTitle":932,"status":558,"phases":933,"primaryCompletion":934,"completion":934,"start":935,"enrollment":936,"conditions":937,"interventions":939},"NCT03879252","Tolerance of Teeth Brushing During Prolonged Aplasia",[91],"2023-02-01","2019-07-22",76,[938],"Aplasia",[920],{"trials":941,"activeCount":101},[],{"trials":943,"activeCount":101},[],{"intervention":945,"totalTrials":137,"cells":946},"RP103",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":965,"NA":967},{"trials":948,"activeCount":101},[],{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[],{"trials":954,"activeCount":101},[955],{"nctId":956,"briefTitle":957,"status":109,"phases":958,"primaryCompletion":959,"start":960,"enrollment":961,"conditions":962,"interventions":964},"NCT02101957","Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)",[90,91],"2015-07","2010-10",96,[963],"Huntington's Disease",[945],{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":101},[],{"intervention":970,"totalTrials":137,"cells":971},"Carboplatin",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":992,"NA":994},{"trials":973,"activeCount":101},[],{"trials":975,"activeCount":101},[],{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[980],{"nctId":981,"briefTitle":982,"status":109,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT02738346","SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013",[91],"2017-07","2013-07",164,[988],"Small Cell Lung Cancer",[970,990,991],"Etoposide","Topotecan",{"trials":993,"activeCount":101},[],{"trials":995,"activeCount":101},[],{"intervention":990,"totalTrials":137,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":101},[],{"trials":1001,"activeCount":101},[],{"trials":1003,"activeCount":101},[],{"trials":1005,"activeCount":101},[1006],{"nctId":981,"briefTitle":982,"status":109,"phases":1007,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":1008,"interventions":1009},[91],[988],[970,990,991],{"trials":1011,"activeCount":101},[],{"trials":1013,"activeCount":101},[],{"intervention":991,"totalTrials":137,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1017,"activeCount":101},[],{"trials":1019,"activeCount":101},[],{"trials":1021,"activeCount":101},[],{"trials":1023,"activeCount":101},[1024],{"nctId":981,"briefTitle":982,"status":109,"phases":1025,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":1026,"interventions":1027},[91],[988],[970,990,991],{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":101},[],{"intervention":1033,"totalTrials":137,"cells":1034},"epoetin beta",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1053,"NA":1055},{"trials":1036,"activeCount":101},[],{"trials":1038,"activeCount":101},[],{"trials":1040,"activeCount":101},[],{"trials":1042,"activeCount":101},[1043],{"nctId":1044,"briefTitle":1045,"status":558,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1052},"NCT00262379","Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C",[91],"2009-06","2005-12",229,[1051],"Chronic Hepatitis C",[1033],{"trials":1054,"activeCount":101},[],{"trials":1056,"activeCount":101},[],{"intervention":1058,"totalTrials":137,"cells":1059},"Memantine",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1078,"NA":1080},{"trials":1061,"activeCount":101},[],{"trials":1063,"activeCount":101},[],{"trials":1065,"activeCount":101},[],{"trials":1067,"activeCount":101},[1068],{"nctId":1069,"briefTitle":1070,"status":558,"phases":1071,"primaryCompletion":618,"completion":618,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1075},"NCT01409694","Alzheimer's Disease - Input of Vitamin D With mEmantine Assay",[91],"2011-09",90,[34],[1058,1076,1077],"Vitamin D","Vitamin D placebo",{"trials":1079,"activeCount":101},[],{"trials":1081,"activeCount":101},[],{"intervention":1076,"totalTrials":137,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":101},[],{"trials":1087,"activeCount":101},[],{"trials":1089,"activeCount":101},[],{"trials":1091,"activeCount":101},[1092],{"nctId":1069,"briefTitle":1070,"status":558,"phases":1093,"primaryCompletion":618,"completion":618,"start":1072,"enrollment":1073,"conditions":1094,"interventions":1095},[91],[34],[1058,1076,1077],{"trials":1097,"activeCount":101},[],{"trials":1099,"activeCount":101},[],{"intervention":1077,"totalTrials":137,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[],{"trials":1107,"activeCount":101},[],{"trials":1109,"activeCount":101},[1110],{"nctId":1069,"briefTitle":1070,"status":558,"phases":1111,"primaryCompletion":618,"completion":618,"start":1072,"enrollment":1073,"conditions":1112,"interventions":1113},[91],[34],[1058,1076,1077],{"trials":1115,"activeCount":101},[],{"trials":1117,"activeCount":101},[],{"intervention":1119,"totalTrials":137,"cells":1120},"Opioid Free Anaesthesia protocol",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1144,"NA":1146},{"trials":1122,"activeCount":101},[],{"trials":1124,"activeCount":101},[],{"trials":1126,"activeCount":101},[],{"trials":1128,"activeCount":101},[1129],{"nctId":1130,"briefTitle":1131,"status":109,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1142},"NCT04797312","Comparison of an Opioid-Free Anesthesia Protocol Versus Standard Practices on Early and Late Post-operative Recovery",[91],"2022-11","2023-05","2021-07-12",140,[1138,1139,1140,1141],"Anesthesia","Anesthesia; Adverse Effect","Opioid Analgesic Adverse Reaction","Post-Op Complication",[1119,1143],"standard practice protocol based on the use of opioids",{"trials":1145,"activeCount":101},[],{"trials":1147,"activeCount":101},[],{"intervention":1143,"totalTrials":137,"cells":1149},{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1162,"NA":1164},{"trials":1151,"activeCount":101},[],{"trials":1153,"activeCount":101},[],{"trials":1155,"activeCount":101},[],{"trials":1157,"activeCount":101},[1158],{"nctId":1130,"briefTitle":1131,"status":109,"phases":1159,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1136,"conditions":1160,"interventions":1161},[91],[1138,1139,1140,1141],[1119,1143],{"trials":1163,"activeCount":101},[],{"trials":1165,"activeCount":101},[],{"intervention":1167,"totalTrials":137,"cells":1168},"human serum albumin",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1185,"NA":1187},{"trials":1170,"activeCount":101},[],{"trials":1172,"activeCount":101},[],{"trials":1174,"activeCount":101},[],{"trials":1176,"activeCount":101},[1177],{"nctId":1178,"briefTitle":1179,"status":109,"phases":1180,"enrollment":1181,"conditions":1182,"interventions":1184},"NCT00152685","High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury",[90,91],40,[1183],"Severe Head Injury",[1167],{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":101},[],{"intervention":1190,"totalTrials":137,"cells":1191},"Optimal medical treatment",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1210,"NA":1212},{"trials":1193,"activeCount":101},[],{"trials":1195,"activeCount":101},[],{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":101},[1200],{"nctId":1201,"briefTitle":1202,"status":615,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":911,"conditions":1206,"interventions":1208},"NCT03746054","Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality",[91],"2024-04-16","2019-12-20",[1207],"Chronic Myeloid Leukemia (CML)",[1190,1209],"usual clinical practice",{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":101},[],{"intervention":1209,"totalTrials":137,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":101},[],{"trials":1221,"activeCount":101},[],{"trials":1223,"activeCount":101},[1224],{"nctId":1201,"briefTitle":1202,"status":615,"phases":1225,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":911,"conditions":1226,"interventions":1227},[91],[1207],[1190,1209],{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"intervention":1233,"totalTrials":137,"cells":1234},"IOHEXOL",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1241,"PHASE4":1254,"NA":1256},{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"trials":1242,"activeCount":101},[1243],{"nctId":1244,"briefTitle":1245,"status":109,"phases":1246,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1253},"NCT02961478","Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure",[91],"2020-06","2020-12","2017-02-10",150,[1252],"Acute Renal Failure",[1233],{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[],{"intervention":1259,"totalTrials":137,"cells":1260},"Sildenafil 100 mg oral morning dose",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1277,"NA":1279},{"trials":1262,"activeCount":101},[],{"trials":1264,"activeCount":101},[],{"trials":1266,"activeCount":101},[],{"trials":1268,"activeCount":101},[1269],{"nctId":1270,"briefTitle":1271,"status":589,"phases":1272,"primaryCompletion":1273,"enrollment":101,"conditions":1274,"interventions":1276},"NCT02930811","Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication",[91],"2022-10",[1275],"Peripheral Arterial Occlusive Disease",[1259],{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"intervention":1282,"totalTrials":137,"cells":1283},"Lecitone®Se-Vitamin D3",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1302,"NA":1304},{"trials":1285,"activeCount":101},[],{"trials":1287,"activeCount":101},[],{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":101},[1292],{"nctId":1293,"briefTitle":1294,"status":109,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT01708005","DIetary Supplements, Executive funcTions and Vitamin D (DIET-D)",[90,91],"2014-11","2012-11",160,[1300],"Mild Cognitive Impairment",[1282],{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"intervention":1307,"totalTrials":137,"cells":1308},"Milrinone 1 Mg\u002FmL Solution for",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1329,"NA":1331},{"trials":1310,"activeCount":101},[],{"trials":1312,"activeCount":101},[],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[1317],{"nctId":1318,"briefTitle":1319,"status":558,"phases":1320,"primaryCompletion":1321,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT04362527","Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage",[91],"2025-10-11","2026-01-12","2020-08-10",370,[1326],"Vasospasm",[1307,1328],"Saline solution for",{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"intervention":1328,"totalTrials":137,"cells":1334},{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1347,"NA":1349},{"trials":1336,"activeCount":101},[],{"trials":1338,"activeCount":101},[],{"trials":1340,"activeCount":101},[],{"trials":1342,"activeCount":101},[1343],{"nctId":1318,"briefTitle":1319,"status":558,"phases":1344,"primaryCompletion":1321,"completion":1322,"start":1323,"enrollment":1324,"conditions":1345,"interventions":1346},[91],[1326],[1307,1328],{"trials":1348,"activeCount":101},[],{"trials":1350,"activeCount":101},[],{"intervention":1352,"totalTrials":137,"cells":1353},"LRA Loco-regional anesthesia",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1374,"NA":1376},{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[1362],{"nctId":1363,"briefTitle":1364,"status":558,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1373},"NCT05345639","Chest Wall Block After Sternotomy: Randomized Controlled Trial in Cardiac Surgery: (PABLOS Study)",[91],"2023-08-08","2023-09-07","2022-08-01",254,[1371,1372],"Pain, Postoperative","Cardiac Surgery",[1352],{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":101},[],{"intervention":887,"totalTrials":137,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":101},[],{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":101},[1388],{"nctId":877,"briefTitle":878,"status":615,"phases":1389,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":1390,"interventions":1391},[91],[884,885],[887,855,888,889],{"trials":1393,"activeCount":101},[],{"trials":1395,"activeCount":101},[],{"intervention":888,"totalTrials":137,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":101},[],{"trials":1401,"activeCount":101},[],{"trials":1403,"activeCount":101},[],{"trials":1405,"activeCount":101},[1406],{"nctId":877,"briefTitle":878,"status":615,"phases":1407,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":1408,"interventions":1409},[91],[884,885],[887,855,888,889],{"trials":1411,"activeCount":101},[],{"trials":1413,"activeCount":101},[],{"intervention":889,"totalTrials":137,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":101},[],{"trials":1419,"activeCount":101},[],{"trials":1421,"activeCount":101},[],{"trials":1423,"activeCount":101},[1424],{"nctId":877,"briefTitle":878,"status":615,"phases":1425,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":1426,"interventions":1427},[91],[884,885],[887,855,888,889],{"trials":1429,"activeCount":101},[],{"trials":1431,"activeCount":101},[],{"intervention":1433,"totalTrials":137,"cells":1434},"Erythropoietin",{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1454,"NA":1456},{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":101},[1443],{"nctId":1444,"briefTitle":1445,"status":109,"phases":1446,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1453},"NCT05080049","Erythropoietin to Improve Critical Care Patient Outcomes",[91],"2022-09-02","2022-12-31","2022-01-28",42,[885,1452],"Intensive Care",[1433],{"trials":1455,"activeCount":101},[],{"trials":1457,"activeCount":101},[],{"intervention":1459,"totalTrials":137,"cells":1460},"Selenium",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1482,"NA":1484},{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[],{"trials":1468,"activeCount":101},[1469],{"nctId":1470,"briefTitle":1471,"status":558,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1480},"NCT04080622","Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.",[91],"2023-10-08","2023-10-31","2019-10-10",100,[1478,1479],"Mucositis Oral","Stem Cell Transplant Complications",[1459,1481],"Placebos",{"trials":1483,"activeCount":101},[],{"trials":1485,"activeCount":101},[],{"intervention":1481,"totalTrials":137,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1500,"NA":1502},{"trials":1489,"activeCount":101},[],{"trials":1491,"activeCount":101},[],{"trials":1493,"activeCount":101},[],{"trials":1495,"activeCount":101},[1496],{"nctId":1470,"briefTitle":1471,"status":558,"phases":1497,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":1476,"conditions":1498,"interventions":1499},[91],[1478,1479],[1459,1481],{"trials":1501,"activeCount":101},[],{"trials":1503,"activeCount":101},[],{"intervention":1505,"totalTrials":137,"cells":1506},"cholecalciferol 200,000 IU",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1524,"NA":1526},{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":101},[1515],{"nctId":1516,"briefTitle":1517,"status":558,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":435,"conditions":1521,"interventions":1522},"NCT04344041","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)",[91],"2021-01-14","2020-04-15",[837],[1505,1523],"cholecalciferol 50,000 IU",{"trials":1525,"activeCount":101},[],{"trials":1527,"activeCount":101},[],{"intervention":1523,"totalTrials":137,"cells":1529},{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1536,"PHASE4":1542,"NA":1544},{"trials":1531,"activeCount":101},[],{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":101},[1538],{"nctId":1516,"briefTitle":1517,"status":558,"phases":1539,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":435,"conditions":1540,"interventions":1541},[91],[837],[1505,1523],{"trials":1543,"activeCount":101},[],{"trials":1545,"activeCount":101},[],{"intervention":1547,"totalTrials":137,"cells":1548},"Reversion",{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1570,"NA":1572},{"trials":1550,"activeCount":101},[],{"trials":1552,"activeCount":101},[],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[1557],{"nctId":1558,"briefTitle":1559,"status":615,"phases":1560,"primaryCompletion":1561,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1569},"NCT01961804","PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma",[91],"2020-02-28","2020-09-03","2014-03",202,[1566,1567,1568],"Coagulation; Intravascular","Craniocerebral Trauma","Haemorrhage",[1547],{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"intervention":1575,"totalTrials":137,"cells":1576},"Sildenafil 100mg single oral dose",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1594,"NA":1596},{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":101},[],{"trials":1582,"activeCount":101},[],{"trials":1584,"activeCount":101},[1585],{"nctId":1586,"briefTitle":1587,"status":558,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT02832570","Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication",[91],"2017-10","2016-11-07",14,[1275],[1575],{"trials":1595,"activeCount":101},[],{"trials":1597,"activeCount":101},[],{"intervention":1599,"totalTrials":137,"cells":1600},"Sildenafil",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1618,"NA":1620},{"trials":1602,"activeCount":101},[],{"trials":1604,"activeCount":101},[],{"trials":1606,"activeCount":101},[],{"trials":1608,"activeCount":101},[1609],{"nctId":1610,"briefTitle":1611,"status":109,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":910,"enrollment":1615,"conditions":1616,"interventions":1617},"NCT02387450","Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication",[90,91],"2017-06","2017-09",400,[27],[1599],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":101},[],{"intervention":1623,"totalTrials":137,"cells":1624},"EPO",{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1626,"activeCount":101},[],{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[1631],{"nctId":1632,"briefTitle":1633,"status":558,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1640},"NCT00648089","EPOMI Study: ErythroPOietin in Myocardial Infarction",[90],"2010-12","2008-04",110,[1639],"Myocardial Infarction",[1623],{"trials":1642,"activeCount":101},[],{"trials":1644,"activeCount":101},[],{"trials":1646,"activeCount":101},[],{"intervention":1648,"totalTrials":137,"cells":1649},"dasatinib",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1651,"activeCount":101},[],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[1656],{"nctId":1657,"briefTitle":1658,"status":558,"phases":1659,"primaryCompletion":1660,"start":1661,"enrollment":670,"conditions":1662,"interventions":1664},"NCT02113319","Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia",[90],"2012-05","2007-04",[1663],"Acute Myelogenous Leukemia",[1648],{"trials":1666,"activeCount":101},[],{"trials":1668,"activeCount":101},[],{"trials":1670,"activeCount":101},[],{"intervention":1672,"totalTrials":1673,"cells":1674},"blood sample",3,{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1676,"activeCount":101},[],{"trials":1678,"activeCount":101},[],{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":101},[],{"trials":1686,"activeCount":101},[1687,1696,1708],{"nctId":1688,"briefTitle":1689,"status":109,"phases":1690,"primaryCompletion":1691,"completion":1691,"start":1692,"enrollment":1250,"conditions":1693,"interventions":1695},"NCT03296176","Metabolomic Study in Huntington's Disease (METABO-HD)",[93],"2019-09","2017-10-09",[1694],"Huntington Disease",[1672],{"nctId":1697,"briefTitle":1698,"status":558,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1706},"NCT05758480","Characterization of the Immunometabolic Signature in Long COVID-19.",[93],"2025-05-07","2025-11-03","2023-05-24",62,[1705],"Long COVID",[1707],"Blood sample",{"nctId":1709,"briefTitle":1710,"status":558,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":460,"conditions":1714,"interventions":1717},"NCT03541213","Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)",[93],"2020-09-07","2019-01-23",[1715,1716],"Iron-deficiency","Valvular Heart Disease",[1672],{"intervention":1719,"totalTrials":97,"cells":1720},"sodium nitroprusside",{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1722,"activeCount":101},[],{"trials":1724,"activeCount":101},[],{"trials":1726,"activeCount":101},[],{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[1733,1752],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1736,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1740,"interventions":1742},"NCT00152724","Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers",[],"2008-11","1996-01",85,[1741],"Healthy Volunteers",[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],"scopolamin","emla","capsaicin","aspirin","clopidogrel","celecoxib","indomethacin","acetylcholine","brethyllium",{"nctId":1753,"briefTitle":1754,"status":109,"phases":1755,"completion":1756,"start":1757,"enrollment":1073,"conditions":1758,"interventions":1760},"NCT00160927","Microvascular Response in Diabetes Mellitus",[],"2008-01","2003-01",[1759],"Diabetes Mellitus",[1761,1719],"actylcholine",{"intervention":1763,"totalTrials":97,"cells":1764},"ropivacaine",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1785},{"trials":1766,"activeCount":101},[],{"trials":1768,"activeCount":101},[],{"trials":1770,"activeCount":101},[],{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[1775],{"nctId":1776,"briefTitle":1777,"status":558,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":503,"conditions":1782,"interventions":1784},"NCT01052974","Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol",[92],"2010-05","2010-11-09","2009-03-26",[1783],"Femoral Neck Fracture",[1763],{"trials":1786,"activeCount":101},[1787],{"nctId":1788,"briefTitle":1789,"status":558,"phases":1790,"completion":1791,"start":1792,"enrollment":503,"conditions":1793,"interventions":1796},"NCT00150865","Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery",[93],"2002-03","2001-09",[1794,1795],"Pain","Postoperative",[1763],{"intervention":1798,"totalTrials":137,"cells":1799},"maintain mean arterial pressure between 80-85 mm Hg",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1801,"activeCount":101},[],{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":101},[],{"trials":1809,"activeCount":101},[],{"trials":1811,"activeCount":101},[1812],{"nctId":1813,"briefTitle":1814,"status":558,"phases":1815,"primaryCompletion":1816,"completion":1816,"start":1817,"enrollment":1818,"conditions":1819,"interventions":1824},"NCT01149278","Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock",[93],"2012-09","2010-03",800,[24,1820,1821,1822,1823],"Arterial Pressure","Hemodynamics","Mortality","Clinical Trial",[1798],{"intervention":1826,"totalTrials":137,"cells":1827},"Amoxicillin",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[1840],{"nctId":1841,"briefTitle":1842,"status":558,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1849},"NCT04922034","Outcome of Patients After a Negative Oral Challenge to Amoxicillin",[],"2022-07-18","2022-01-13",190,[1848],"Negative Challenge to Amoxicillin",[1826],{"intervention":1851,"totalTrials":137,"cells":1852},"Women at high risk of MAP",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1854,"activeCount":101},[],{"trials":1856,"activeCount":101},[],{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[],{"trials":1864,"activeCount":101},[1865],{"nctId":1866,"briefTitle":1867,"status":109,"phases":1868,"primaryCompletion":1869,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1878},"NCT02784886","Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta",[],"2015-11","2016-11","2013-11",63,[1874,1875,1876,1877],"Morbidly Adherent Placenta","Placenta Accreta","Placenta Increta","Placenta Percreta",[1851],{"intervention":1743,"totalTrials":137,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1882,"activeCount":101},[],{"trials":1884,"activeCount":101},[],{"trials":1886,"activeCount":101},[],{"trials":1888,"activeCount":101},[],{"trials":1890,"activeCount":101},[],{"trials":1892,"activeCount":101},[1893],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1894,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1895,"interventions":1896},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1744,"totalTrials":137,"cells":1898},{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1903,"PHASE3":1905,"PHASE4":1907,"NA":1909},{"trials":1900,"activeCount":101},[],{"trials":1902,"activeCount":101},[],{"trials":1904,"activeCount":101},[],{"trials":1906,"activeCount":101},[],{"trials":1908,"activeCount":101},[],{"trials":1910,"activeCount":101},[1911],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1912,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1913,"interventions":1914},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1745,"totalTrials":137,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1923,"PHASE4":1925,"NA":1927},{"trials":1918,"activeCount":101},[],{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[],{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[1929],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1930,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1931,"interventions":1932},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1746,"totalTrials":137,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[],{"trials":1940,"activeCount":101},[],{"trials":1942,"activeCount":101},[],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[1947],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1948,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1949,"interventions":1950},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1747,"totalTrials":137,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":101},[],{"trials":1958,"activeCount":101},[],{"trials":1960,"activeCount":101},[],{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[1965],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1966,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1967,"interventions":1968},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1748,"totalTrials":137,"cells":1970},{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1972,"activeCount":101},[],{"trials":1974,"activeCount":101},[],{"trials":1976,"activeCount":101},[],{"trials":1978,"activeCount":101},[],{"trials":1980,"activeCount":101},[],{"trials":1982,"activeCount":101},[1983],{"nctId":1734,"briefTitle":1735,"status":558,"phases":1984,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":1985,"interventions":1986},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1749,"totalTrials":137,"cells":1988},{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[],{"trials":1994,"activeCount":101},[],{"trials":1996,"activeCount":101},[],{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[2001],{"nctId":1734,"briefTitle":1735,"status":558,"phases":2002,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":2003,"interventions":2004},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1750,"totalTrials":137,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2015,"NA":2017},{"trials":2008,"activeCount":101},[],{"trials":2010,"activeCount":101},[],{"trials":2012,"activeCount":101},[],{"trials":2014,"activeCount":101},[],{"trials":2016,"activeCount":101},[],{"trials":2018,"activeCount":101},[2019],{"nctId":1734,"briefTitle":1735,"status":558,"phases":2020,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":2021,"interventions":2022},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":1751,"totalTrials":137,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":101},[],{"trials":2036,"activeCount":101},[2037],{"nctId":1734,"briefTitle":1735,"status":558,"phases":2038,"primaryCompletion":1737,"completion":1737,"start":1738,"enrollment":1739,"conditions":2039,"interventions":2040},[],[1741],[1743,1744,1745,1746,1747,1748,1749,1750,1719,1751],{"intervention":2042,"totalTrials":137,"cells":2043},"GENETIC ANALYSIS",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2045,"activeCount":101},[],{"trials":2047,"activeCount":101},[],{"trials":2049,"activeCount":101},[],{"trials":2051,"activeCount":101},[],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":101},[2056],{"nctId":2057,"briefTitle":2058,"status":558,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":35,"conditions":2062,"interventions":2064},"NCT02704260","Genetic of SportS Induced Endofibrotic Remodeling",[93],"2016-09-02","2016-03-02",[2063],"Genetic Syndrome",[2042],{"intervention":2066,"totalTrials":137,"cells":2067},"arterial blood gas measurement each morning",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":101},[],{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":101},[],{"trials":2079,"activeCount":101},[2080],{"nctId":2081,"briefTitle":2082,"status":109,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":2086,"enrollment":2087,"conditions":2088,"interventions":2090},"NCT01862016","Early Spontaneous Breathing in Acute Respiratory Distress Syndrome",[93],"2017-12-16","2019-05","2013-02-28",702,[2089],"Acute Respiratory Distress Syndrome",[2066],{"intervention":2092,"totalTrials":137,"cells":2093},"Drug intervention",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2095,"activeCount":101},[],{"trials":2097,"activeCount":101},[],{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":101},[],{"trials":2105,"activeCount":101},[2106],{"nctId":2107,"briefTitle":2108,"status":109,"phases":2109,"primaryCompletion":2110,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2117},"NCT01315704","Alzheimer's Disease and Related Disorders",[],"2017-11","2009-11",700,[2114,2115,2116],"Alzheimer's Disease","Gait Apraxia","Impaired Cognition",[2092],{"intervention":2119,"totalTrials":137,"cells":2120},"acetylsalicilic acids",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2122,"activeCount":101},[],{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[],{"trials":2128,"activeCount":101},[],{"trials":2130,"activeCount":101},[],{"trials":2132,"activeCount":101},[2133],{"nctId":2134,"briefTitle":2135,"status":558,"phases":2136,"primaryCompletion":792,"completion":2137,"start":2138,"enrollment":2139,"conditions":2140,"interventions":2142},"NCT01572961","Microvascular Function Assessment in Healthy Subjects",[93],"2013-05","2010-11",16,[2141],"Physiology of Microvascular Skin",[2119],{"intervention":2144,"totalTrials":137,"cells":2145},"Renin measurement",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2147,"activeCount":101},[],{"trials":2149,"activeCount":101},[],{"trials":2151,"activeCount":101},[],{"trials":2153,"activeCount":101},[],{"trials":2155,"activeCount":101},[],{"trials":2157,"activeCount":101},[2158],{"nctId":2159,"briefTitle":2160,"status":109,"phases":2161,"primaryCompletion":2162,"completion":2162,"start":984,"enrollment":2163,"conditions":2164,"interventions":2168},"NCT03218319","Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)",[93],"2018-12",200,[2165,2166,2167],"Renal Cancer","Nephrectomy","Blood Pressure",[2144],{"intervention":2170,"totalTrials":137,"cells":2171},"paracetamol",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2173,"activeCount":101},[],{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[],{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":101},[2184],{"nctId":2185,"briefTitle":2186,"status":558,"phases":2187,"completion":2188,"start":2189,"enrollment":2190,"conditions":2191,"interventions":2193},"NCT00188071","Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen",[93],"2003-08","2002-09",240,[2192],"Abortion, Induced",[2170,2194,2195],"ketoprofen","ketoprofen + paracetamol",{"intervention":2194,"totalTrials":137,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2199,"activeCount":101},[],{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[2210],{"nctId":2185,"briefTitle":2186,"status":558,"phases":2211,"completion":2188,"start":2189,"enrollment":2190,"conditions":2212,"interventions":2213},[93],[2192],[2170,2194,2195],{"intervention":2195,"totalTrials":137,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2217,"activeCount":101},[],{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[],{"trials":2227,"activeCount":101},[2228],{"nctId":2185,"briefTitle":2186,"status":558,"phases":2229,"completion":2188,"start":2189,"enrollment":2190,"conditions":2230,"interventions":2231},[93],[2192],[2170,2194,2195],{"intervention":2233,"totalTrials":137,"cells":2234},"Capillary blood sampling from the earlobe",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"trials":2242,"activeCount":101},[],{"trials":2244,"activeCount":101},[],{"trials":2246,"activeCount":101},[2247],{"nctId":2248,"briefTitle":2249,"status":558,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT03305198","BIOlogical Response to Exercise : A Metabolomic Study in Peripheral Artery Disease (BIOR)",[93],"2019-03-18","2017-10-01",69,[15],[2233],{"intervention":2257,"totalTrials":137,"cells":2258},"Estradiol 2 MG",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[],{"trials":2264,"activeCount":101},[],{"trials":2266,"activeCount":101},[],{"trials":2268,"activeCount":101},[],{"trials":2270,"activeCount":101},[2271],{"nctId":2272,"briefTitle":2273,"status":109,"phases":2274,"primaryCompletion":591,"completion":2162,"start":2275,"enrollment":1476,"conditions":2276,"interventions":2279},"NCT03518528","Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer",[],"2018-08-30",[2277,2278],"Embryo Transfer","Infertility",[2257,2280],"Estradiol 100 µg",{"intervention":2280,"totalTrials":137,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2284,"activeCount":101},[],{"trials":2286,"activeCount":101},[],{"trials":2288,"activeCount":101},[],{"trials":2290,"activeCount":101},[],{"trials":2292,"activeCount":101},[],{"trials":2294,"activeCount":101},[2295],{"nctId":2272,"briefTitle":2273,"status":109,"phases":2296,"primaryCompletion":591,"completion":2162,"start":2275,"enrollment":1476,"conditions":2297,"interventions":2298},[],[2277,2278],[2257,2280],{"intervention":2300,"totalTrials":137,"cells":2301},"blood sampling",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2303,"activeCount":101},[],{"trials":2305,"activeCount":101},[],{"trials":2307,"activeCount":101},[],{"trials":2309,"activeCount":101},[],{"trials":2311,"activeCount":101},[],{"trials":2313,"activeCount":101},[2314],{"nctId":2315,"briefTitle":2316,"status":109,"phases":2317,"primaryCompletion":2318,"completion":2319,"start":2320,"enrollment":1476,"conditions":2321,"interventions":2323},"NCT04337190","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)",[],"2020-10-06","2020-12-06","2020-04-03",[2322,2089],"COVID",[2300],{"intervention":1761,"totalTrials":137,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2327,"activeCount":101},[],{"trials":2329,"activeCount":101},[],{"trials":2331,"activeCount":101},[],{"trials":2333,"activeCount":101},[],{"trials":2335,"activeCount":101},[],{"trials":2337,"activeCount":101},[2338],{"nctId":1753,"briefTitle":1754,"status":109,"phases":2339,"completion":1756,"start":1757,"enrollment":1073,"conditions":2340,"interventions":2341},[],[1759],[1761,1719],{"intervention":2343,"totalTrials":137,"cells":2344},"Growth hormone",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[],{"trials":2352,"activeCount":101},[],{"trials":2354,"activeCount":101},[],{"trials":2356,"activeCount":101},[2357],{"nctId":2358,"briefTitle":2359,"status":109,"phases":2360,"completion":2361,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2366},"NCT00187993","Growth Hormone Treatment of Young Growth Hormone-Deficient Adults",[],"2005-08","2005-05",30,[2365],"Growth Hormone Deficiency",[2343],{"intervention":2368,"totalTrials":137,"cells":2369},"oxygen and saline",{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2371,"activeCount":101},[],{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[],{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[2382],{"nctId":2383,"briefTitle":2384,"status":615,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":2388,"conditions":2389,"interventions":2391},"NCT01722422","Hyperoxia and Hypertonic Saline in Septic Shock",[93],"2014-09","2012-10",441,[24,2390],"Adult Respiratory Distress Syndrome",[2368]]